Key result
OLFM2 expression in subcutaneous adipose tissue was enhanced in women with morbid obesity and NAFLD, while its expression in visceral adipose tissue decreased in the presence of NASH.
Why the study?
The study was conducted to assess the involvement of olfactomedin 2, a secreted glycoprotein related to lipid metabolism regulation, in nonalcoholic fatty liver disease mediated by the adipose tissue-liver axis.
Observational (n=76)
OLFM2 expression in subcutaneous adipose tissue is associated with hepatic lipid accumulation and may play a role in the development of NAFLD in morbidly obese women.
OLFM2 upregulation in SAT associates with NAFLD in obesity; leaves open causal role in adipose-liver axis pending prospective validation.
This study's objective was to assess the involvement of olfactomedin 2 (OLFM2), a secreted glycoprotein related to lipid metabolism regulation, in nonalcoholic fatty liver disease (NAFLD) mediated by the adipose-tissue-liver axis. OLFM2 mRNA expression was analyzed in subcutaneous (SAT) and visceral (VAT) adipose tissue by RT-qPCR. The cohort included women with normal weight (n = 16) or morbid obesity (MO, n = 60) who were subclassified into normal liver (n = 20), simple steatosis (n = 21), and nonalcoholic steatohepatitis (NASH, n = 19) groups. The results showed that OLFM2 expression in SAT was enhanced in MO individuals and in the presence of NAFLD. Specifically, OLFM2 expression in SAT was increased in mild and moderate degrees of steatosis in comparison to the absence of it. Moreover, OLFM2 expression in SAT was negatively correlated with interleukin-6 levels. On the other hand, OLFM2 expression in VAT decreased in the presence of NASH and exhibited a positive correlation with adiponectin levels. In conclusion, OLFM2 in SAT seems to be implicated in hepatic lipid accumulation. Additionally, since we previously suggested the possible implication of hepatic OLFM2 in NAFLD progression, now we propose a possible interaction between the liver and SAT, reinforcing the potential implication of this tissue in NAFLD development.
No takes yet. Share an insight, caveat, or question.
Barrientos‐Riosalido et al. (2023) conducted an observational in Nonalcoholic fatty liver disease (NAFLD) and obesity (n=76). Morbid obesity and NAFLD vs. Normal weight and normal liver was evaluated on OLFM2 mRNA expression in subcutaneous and visceral adipose tissue. OLFM2 expression in subcutaneous adipose tissue was enhanced in women with morbid obesity and NAFLD, while its expression in visceral adipose tissue decreased in the presence of NASH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: